

Antagonistic Activity Exhibited by Crude Extracts of *Pseudomonas aeruginosa* (PIC-4) against *Aeromonas hydrophila* and *E. coli*

M. Veerendra Kumar and Janakiram Pasupuleti

Department of Marine Living Resources, Andhra University, Visakhapatnam, 530003, India

Email: {veerendratech, pasupuleti9999}@gmail.com

Murali Krishna Kumar M.

Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, India

Email: drmmkau@gmail.com

Abstract—*Pseudomonas aeruginosa* (PIC-4) (Genbank accession No: KF803248) was isolated from Coastal waters of Visakhapatnam. Cell free culture broth of the isolate exhibited antagonistic activity against pathogenic bacteria *Aeromonas hydrophila* and *E. coli* in agar well diffusion method with the diameter of inhibition zones 30mm and 36 mm respectively. Optimum temperature and time for growth and antibiotic production were standardised as 28 °C and 48 hrs respectively and optimum NaCl concentration was determined as 1%, in addition to the LB broth medium. Two solvent fractions, F1 and F3 obtained on 100% hexane and ethyl acetate: hexane (1:1) respectively exhibited antibacterial activity against tested pathogens. F1, a colourless with low melting crystals found to have more antibacterial activity than that of F3, colourless short needles. Minimum inhibition concentration of both F1 and F3 were recorded as 32µg/ml on *E. coli* and 64µg/ml *Aeromonas hydrophila*.

Index Terms—*Pseudomonas aeruginosa*, *Aeromonas hydrophila*, *E. coli*, antibacterial activity

I. INTRODUCTION

Genus *Pseudomonas* is found in natural habitats like soil, freshwater, marine environments and is familiar with production of a remarkable array of secondary metabolites [1]. Aquatic *Pseudomonads* are often antagonistic against other microorganisms by producing a diverse range of potent antimicrobial compounds, some *Pseudomonas* biocontrol strains have been developed into commercial products, e.g., *P. chlororaphis* MA342. (Cedomon, Cerall) [2]. *A. hydrophila* cause disease in aquatic animals, such as red leg disease which is caused by endotoxin and haemolysin produced by the bacteria [3], [4]. In humans, *Aeromonas hydrophila* causes gastrointestinal infections such as watery diarrhoea to dysenteric or bloody diarrhoea [5] and non-gastrointestinal complications include haemolytic syndrome, kidney disease, cellulitis, wound & soft-tissue

infection, meningitis, and septicemia [6], [7]. *Escherichia coli* belongs to normal microflora of the gastrointestinal tract, but certain *E. coli* strains are associated with urinogenital diseases, pleuro-pneumonitis, gastroenteritis and septicaemia [8], also causes traveler's diarrhoea [9]. The morbidity and mortality associated with several recent large outbreaks of gastrointestinal disease caused by *E. coli* has highlighted the threat to public health [8]. The discovery of antimicrobial compounds produced by organisms isolated from different environments might provide new or more-efficient means for the inhibition of selected microorganisms [10].

II. MATERIALS AND METHODS

A. Antagonistic Activity

Pathogenic indicator bacteria *Aeromonas hydrophila* (MTCC: 1739) and *E. coli* (MTCC: 1678) were obtained from Microbial Type Culture Collection (MTCC) Chandigarh India. *Pseudomonas aeruginosa* (PIC4) was isolated from Coastal water of Visakhapatnam. Antibacterial activity of the isolate was tested by agar well diffusion method against indicator bacteria *Aeromonas hydrophila* and *E. coli*. Ten mille letters of 18 hrs young culture of *P. Aeruginosa* (PIC4) grown in Luria Bertani (LB) broth medium (Himedia, India) was centrifuged at 5000g. The cell free supernatant broth was concentrated under reduced pressure (Buschi-210) at 30 °C and diluted in 1 ml of double distilled water and stored at 4 °C. 100µl of each 18hr young culture of *A. hydrophila* and *E.coli* cultured in LB broth were spread on LB agar plates. Wells of 1 cm diameter were made at the centre of the agar dish with sterile cork borer. The concentrated cell free culture broth (100µl) of *P. aeruginosa* PIC 4 was directly filled in the wells of agar dishes pre-inoculated with indicator bacteria. Diameter of inhibition zone was measured after 24 hrs of incubation at 28 °C. Filtered cell free culture broths (through 0.22µm and 0.45µm porosity) were also tested for antagonistic activity.

B. Optimum Temperature, Time and Sodium Chloride (NaCl) Concentration

Upon confirmation of antibacterial activity, culture conditions of the *P. aeruginosa* (PIC4) were optimised in order to maximise the production of secondary metabolites [11]. *P. aeruginosa* PI C4 was cultured in 250ml conical flasks (5 Nos) containing 100ml of LB broth and incubated at various temperatures viz 25, 28, 30, 35 and 40 °C on orbital shaker at 100rpm. Hundred micro litres of concentrated cell free broth samples obtained (as mentioned in II.A) at various time intervals (12, 24, 36, 48, 60 & 72 hrs) were subjected to antibacterial screening by agar well diffusion method [12] against *A. hydrophila* and *E. coli*. Diameter of inhibition zone was measured after 24 hrs of incubation at 28 °C. The bacterial count was measured by reading the Optical Density (OD) at 600nm and serial dilution followed by spread plate method. Optimum NaCl concentration was standardised by supplemented LB broth with 0.5, 1, 1.5, 2 and 5% NaCl. Cell free broth samples from these flasks at optimum time temperature were tested for antimicrobial activity and followed by enumeration of bacterial count (as mentioned above).

C. Preparation of Crude Extract

Bulk production of crude extract was achieved by culturing of the isolate PIC4 in 5 litre conical flask (10 No.s) containing 1.8 litre of LB broth added with 1% NaCl at 28 °C for 48 hrs on a rotary shaker moving at 100 rpm. The culture broth was filtered through muslin cloth to get the cell free media. Equal amounts of cell free culture broth and ethyl acetate taken in separating funnel, mixed well and allowed to separate organic and aqueous fractions for 10 minutes and phases were collected separately. Both aqueous and organic phases were tested for antibacterial activity. Only the organic phase was performed to concentrate extract under reduced pressure (Buschi 210) at 30 °C as it alone showed antibacterial activity on tested bacteria.

D. Screening of the Solvent Extracts for Bioactivity

The crude extract obtained was further subjected to fractionation with solvents of increasing polarity viz 100% hexane, 10% ethyl acetate in hexane, 50% ethyl acetate in hexane, 100% ethyl acetate and 100% methanol. Purity of fractions was tested by Thin Layer Chromatography (TLC) and impurities were resolved by re-crystallization using organic solvents. Antimicrobial activity of each purified solvent fraction was further tested by agar well diffusion method briefly; well made on the agar dishes pre-inoculated with indicator bacteria. Each concentrated solvent fraction was dissolved in ethyl acetate (1mg/ml) and 50, 100, 150 & 200 µl of dissolved crude extract (at the concentration of 50, 100, 150 and 200 µg respectively) was directly filled in to the wells of agar dishes pre inoculated with indicator bacteria. The plates were incubated at 28 °C and the diameter of the inhibition zone was measured at 24 hrs of incubation.

E. Minimum Inhibitory Concentration (MIC)

Minimum Inhibitory Concentration (MIC) of purified fractions against the pathogenic bacteria was determined by micro dilution method [13]. One mille litre of the nutrient broth containing the compound (F1 or F3) at various concentrations was distributed in eight sterile test tubes (1 µl to 128 µl) besides keeping a positive and negative control (Table I). The concentration of the compound was maintained in each tube at geometric progression such as 1, 2, 4, 8, 16, 32, 64 and 128 µg/ml. Bacterial suspension of (*A. hydrophila* or *E. coli*) was prepared by dissolving in 5 ml equivalent to a Mc Farland 0.5 standard [13]. 0.1ml of bacterial suspension was added to 9.9ml of saline with a fresh pipette. From which 0.1ml of diluted bacterial suspension transferred to broth tubes containing the compound with varying concentration, numbered 1 through 8 and also to the positive control tube. 0.1ml sterile saline was added to the negative control. Contents in all the tubes were mixed well and incubated for 24 hrs. Test tube containing lowest concentration of the compound with no bacterial growth was considered as minimum inhibitory concentration.

TABLE I. MICRO-DILUTION TUBES CONTAINING COMPOUND CONCENTRATION IN DESCENDING ORDER

Tube No	1	2	3	4	5	6	7	8	9	10
Conc. of the compound µg/ml	128	64	32	16	8	4	2	1	positive control	Negative control

III. RESULTS

A. Optimization of Antagonistic Activity

The diameters of inhibition zones formed by concentrated cell free culture broth were obtained (Fig. 1 & Fig. 2). There was no difference found in diameter of inhibition zone between filtered and unfiltered cell free culture broths. The optimum Temperature and time for growth and antibiotic production were determined as 28 °C and 48 hrs respectively. Even though cell growth reached maximum after 36hrs at 48 °C but inhibitory

secondary metabolite production was very low (Fig. 3 & Fig. 4). Optimum concentration of NaCl was determined as 1% to the LB medium (Fig. 5 & Fig. 6).

B. Bioactivity of Crude Extract

Three grams of dark pungent smelling crude extract obtained on evaporation of organic phase under reduced pressure. Upon five solvent fractions obtained from crude extract, fraction 1 (100% hexane) and fraction 3 (hexane: ethyl acetate 1:1) showed antibacterial activity on both the tested bacteria, while fraction 2, 4 and 5 are devoid of activity (Fig. 7). Fraction 1 (F1) was obtained as viscous

oily liquid with unbearable smell. TLC of F1 has shown one major spot with three other minor spots which were well resolved by re crystallization using acetone and methanol. Purified F1, a colourless with low melting crystals was exhibited antibacterial activity with inhibition zone of 20 & 32mm in dia on *E. coli* and *A. hydrophila* respectively at 200µg concentrations (Table II; Fig. 8). Fraction 3 (F3) showed dark major spot and several closely related spots on TLC which were resolved by re-crystallization using hexane: acetone (60:40). Purified F3, colourless short needles exhibited antibacterial activity with inhibition zone of 32 & 26mm in dia on *E. coli* & *A. hydrophila* respectively at 200µg concentration (Fig. 9).




Figure 1. Antagonistic activity of cell free culture broth of *P. aeruginosa* on *Aeromonas hydrophila*.




Figure 2. Antagonistic activity of cell free culture broth of *P. aeruginosa* on *E. coli*.




Figure 3. Optimal culture conditions of the isolate PIC 4 (Temperature & Time).




Figure 4. Inhibitory secondary metabolite production at various temperature and time intervals.




Figure 5. Growth of PIC4 culture at different NaCl concentrations.




Figure 6. Inhibitory secondary metabolite production at different NaCl concentrations.




Figure 7. Flow chart showing extraction of bioactive compounds.




Figure 8. Agar dish showing inhibition zone formed by F1 solvent extract on *E. coli*.




Figure 9. Agar dish showing inhibition zone formed by F3 solvent extract on *E. coli*.

TABLE II. DIAMETERS OF INHIBITION ZONES FORMED BY SOLVENT FRACTIONS ON INDICATOR BACTERIA

Concentration of Compound in µg	F1		F3	
	Diameter of inhibition zone(mm) on		Diameter of Inhibition zone (mm) on	
	<i>A. hydrophila</i>	<i>E. coli</i>	<i>A. hydrophila</i>	<i>E. coli</i>
50	6	10	8	10
100	10	18	16	14
150	14	26	20	18
200	20	32	22	26

C. Minimal Inhibitory Concentration (MIC)

Minimum Inhibitory Concentration (MIC) of both F1 and F3 fraction were determined as 32 µg/ml on *E. coli* and 64 µg/ml on *Aeromonas hydrophila*.

IV. DISCUSSION

Inhibitory activity of *Pseudomonas* against a number of pathogens such as *Salmonella*, *Staphylococcus aureus* and *V. parahaemolyticus* has been reported since the year 1960 [14]-[18]. Kinetics of any bioorganic reaction depends heavily on the external conditions, where temperature plays a significant role. In our experiment 28 °C is the optimum temperature for production of bioactive compound(s) it is in the optimal temperature range of 25-40 °C earlier reports showed [19]-[21] and 38 °C as observed by Vijayan *et al.* [11]. Generally microbes produce secondary metabolites in the stationary phase. The time duration for this phase is usually 24-48 hrs [22]. In our study, optimal production (peak production) was observed at 48 hours. Earlier reports on various *Pseudomonads* showed an optimal production after 36 hrs [23]-[25]. Vijayan *et al.* has observed peak production of bioactive metabolites from *Pseudomonas* sp. in a 30 hrs culture. Sodium chloride concentration plays major role in the maintenance of osmotic balance [26]. In the tested range of 0.5 to 5%, optimum NaCl concentration required for our microbial isolate was found to be 1%. Similar pattern was also observed for *Pseudomonas* I-2 strain by Chytanya *et al.* [27]. It is assumed that the compound may not be an enzyme or protein since no difference found between in antibacterial activity between filtered and unfiltered culture broth. MICs of our two fractions are in the good range between 32 and 64 µg/ml [13] and form clear inhibition zones in agar diffusion method. A number of earlier studies have also shown that bacteria produce inhibitory substances that inhibit the bacterial pathogens.

V. CONCLUSIONS

Pseudomonas aeruginosa isolated from Marine waters exhibited antibacterial activity. Culture conditions for the isolate were optimized in order to produce maximum zone of inhibition against the tested pathogens. Antibacterial activity was found in the crude extract obtained in the organic phase after fractionation in Ethyl acetate, hexane and Methanol. Two fractions exhibited antibacterial activity against the indicator bacteria tested *A. hydrophila* & *E. coli*. The use of such bacteria which

inhibit pathogens by release of antimicrobial substances is now gaining importance in a better and more effective pathogen control.

ACKNOWLEDGMENT

Authors are grateful to University Grants Commission Govt of India, New Delhi for the financial assistance provided for the Research Scholar.

REFERENCES

- [1] H. Gross and E. L. Joyce, "Genomics of secondary metabolite production by *Pseudomonas* spp.," *Natural Products Reports*, vol. 26, pp. 1408-1446, Nov. 2009.
- [2] L. Johnsson, M. Hokeberg, and B. E. Gerhardsson, "Performance of the *Pseudomonas chlororaphis* biocontrol agent MA 342 against cereal seed-borne diseases in field experiments," *Plant Pathology*, vol. 104, pp. 701-711, Sep. 1998.
- [3] J. Pikul, R. Stefan, E. Lennart, H. Liu, and K. Soderhall, "A highly virulent pathogen, *Aeromonas hydrophila*, from the freshwater crayfish *Pacifastacus leniusculus*," *Journal of Invertebrate Pathology*, vol. 10, pp. 56-66, Apr. 2009.
- [4] M. M. Rigney, J. W. Zilinsky, and M. A. Rouf, "Pathogenicity of *Aeromonas hydrophila* in red leg disease in Frogs," *Current Microbiology*, vol. 1, pp. 175-179, March 1978.
- [5] A. J. Horneman, A. Ali, and S. L. Abbott, "Aeromonas," in *Manual of Clinical Microbiology*, P. R. Murray, E. J. Baron, M. L. Landry, J. H. Jorgensen, and M. A. Pfaller, Eds., 2007, pp. 715-722.
- [6] C. Y. Chang, H. Thompson, N. Rodman, J. Bylander, and J. Thomas, "Pathogenic analysis of *Aeromonas hydrophila* septicemia," *Annals of Clinical and Laboratory Science*, vol. 27 no. 4, pp. 254-259, Jul.-Aug. 1997.
- [7] H. D. Reines and F. V. Cook, "Pneumonia and bacteremia due to *Aeromonas hydrophila*," *Chest*, vol. 80, no. 3, pp. 264-267, Sep. 1981.
- [8] C. P. James and W. P. Adrienne, "Pathogenesis and diagnosis of Shiga toxin-producing *Escherichia coli* infections," *Clinical Microbiology Reviews*, vol. 11 no. 3, pp. 450-479, Jul. 1998.
- [9] M. D. Yates, A. Johnnie, and C. Lori, "Reiter's syndrome (reactive arthritis) and travelers' diarrhea," *Journal of Travel Medicine*, vol. 13, pp. 54-56, Jan.-Feb. 2006.
- [10] F. James, J. R. Novotny, and J. P. Jerome, "Characterization of bacteriocins from Two Strains of *Bacillus thermoleovorans*, a thermophilic hydrocarbon-utilizing species," *Appl. Environ. Microbiology*, vol. 58, no. 8, pp. 2393-2396, Aug. 1992.
- [11] K. K. Vijayan, I. S. Bright Singh, N. S. Jayaprakash, S. V. Alavandi, S. P. Somnath, R. Preetha, *et al.*, "A brackishwater isolate of *Pseudomonas* PS-102, a potential antagonistic bacterium against pathogenic vibrios in penaeid and non-penaeid rearing systems," *Aquaculture*, vol. 251, pp. 192-200, Feb. 2006.
- [12] V. Cleidson, M. Simone, F. A. S. Elza, and S. A. Jr, "Screening methods to determine antibacterial activity of natural products," *Brazilian Journal of Microbiology*, vol. 38, pp. 369-380, Apr.-Jun. 2007.
- [13] J. M. Andrews, "Determination of minimum inhibitory concentrations," *Journal of Antimicrobial Chemistry*, vol. 48, pp. 5-16, July 2001.

- [14] E. N. Seminiano and W. C. Frazier. "Effect of *Pseudomonas* and achromobacteriaceae on growth of *Staphylococcus aureus*," *J. Milk Food Technology*, vol. 29, pp. 161-167, Apr. 1960.
- [15] J. A. Troller and W. C. Frazier, "Repression of *Staphylococcus aureus* by food bacteria, causes inhibition," *Appl. Microbiology*, vol. 11, pp. 11-14, Mar. 1963.
- [16] L. F. Goatcher and D. C. Westhoff, "Repression of *V. parahemolyticus* by *Pseudomonas* sp. isolated from processed crytus," *J. Food Sci.*, vol. 40, pp. 533-536, May 1975.
- [17] C. Daly, M. La Chance, W. E. Sandine, and P. R. Elikier, "Control of *staphylococcus aureus*," *J. Milk Food Sci.*, vol. 38, pp. 426-430, Sep. 1973.
- [18] J. C. Oblinger and A. A. Kreft, "Inhibitory effect of *Pseudomonas* on selected *Salmonella* and bacterial isolates from poultry," *J. Food Sciences*, vol. 35, pp. 30-32, Jan. 1990.
- [19] F. Ritchie, R. A. Bain, and M. P. McQuilken, "Effects of nutrient status, temperature and pH on mycelial growth, sclerotial production and germination of *Rhizoctonia solani* from potato," *Journal of Plant Pathology*, vol. 91, no. 3, pp. 589-596, June 2009.
- [20] L. Elleuch, S. Mohamed, S. Smaoui, L. Mellouli, K. R. Ines, F. Lilia, *et al.*, "Bioactive secondary metabolites from a new terrestrial *Streptomyces* sp. TN262," *Appl. Biochem. Biotechnology*, vol. 162, pp. 579-593, Sep. 2010.
- [21] S. Mathan, S. Vasuki, and N. Sajitha, "Optimization and antimicrobial metabolite production from endophytic fungi *Aspergillus terreus* KC 582297," *European Journal of Experimental Biology*, vol. 3, no. 4, pp. 138-144, June 2013.
- [22] A. W. Bunch and R. E. Harris, "The manipulation of microorganisms for the production of secondary metabolites," *Biotechnol. Genet. Eng. Rev.*, vol. 4, pp. 117-144, Sep. 1986.
- [23] P. Rattanachauy, K. Duangporn, T. Manee, N. Teruhiko, and K. Hiroshi, "Inhibition of shrimp pathogenic vibrios by extracellular compounds from a proteolytic bacterium *Pseudomonas* sp. W3," *Electronic Journal of Biotechnology*, vol. 13, no. 1, pp. 869-888, 2010.
- [24] M. C. Ana, A. Richard, J. W. B. Wilson, and P. K. Nancy, "Relationship between secondary metabolism and fungal development," *Microbiol. Mol. Biol. Rev.*, vol. 66, pp. 3447-3459, Sep. 2002.
- [25] A. S. Shaikh, Y. J. Tang, A. Mukhopadhyay, H. G. Martin, J. Gin, P. I. Benke, *et al.*, "Study of stationary phase metabolism via isotopomer analysis of amino acids from an isolated protein," *Biotechnology Progress*, vol. 26, no. 1, pp. 52-56, Jan.-Feb. 2010.
- [26] R. N. Jennifer, R. M. Ruth, V. N. Guadalupe, and G. M. Nestor, "Effect of pH and salt gradient on the autolysis of *Lactococcus lactis* strains," *Brazilian Journal of Microbiology*, vol. 42, pp. 1495-1499, Oct.-Dec. 2011.
- [27] R. Chythanya, K. Indrani, and K. Iddya, "Inhibition of shrimp pathogenic vibrios by a marine *Pseudomonas* I-2 strain," *Aquaculture*, vol. 208, pp. 1-10, May 2002.



M. Veerendra Kumar has received his MSc degree in biotechnology in 2007 and his PhD in 2014 at the Department of Marine Living Resources in the Andhra University, Visakhapatnam, Andhra Pradesh. His fields of research are microbiology and bioactive marine natural products.



Janakiram Pasupuleti has received his Ph.D. at the Department of Zoology in Andhra University, the M.Tech. (Agril. Engg.) from Indian Institute of Technology, Kharagpur, and the M.Sc. in zoology (fisheries) from Banaras Hindu University, Varanasi. He is currently working as an assistant professor at the Department of Marine Living Resources of Andhra University, Visakhapatnam, India. His field of research is fish pathology (shell fish & finfish).



Murali Krishna Kumar M. has received his Ph.D. in pharmaceutical chemistry in 2006, and the Master degree in pharmaceutical chemistry in 2001 at the Department of Pharmaceutical Chemistry from the Andhra University, Visakhapatnam, India. His fields of research are medicinal chemistry and natural products.